Most Popular
-
1
Yoon sorry for shortcomings but insists policies were right
-
2
1 in 3 Koreans live alone, family types becoming diverse
-
3
S. Korea ‘strongly’ protests Japan’s claim over Dokdo in diplomatic bluebook
-
4
US 'incredibly concerned' about suspected NK-Iran military ties
-
5
Korea, Japan finance chiefs vow to tame rampant FX market volatility
-
6
Korean won weakens amid heightened uncertainty
-
7
Seoul says will cut power to porn festival planned on Han River
-
8
Sewol victims commemorated on tragedy's 10th anniversary
-
9
K-pop group's manager dismissed for setting up spycam in theater dressing room
-
10
Chanel, Louis Vuitton see muted growth in Korea
Nature Cell seeks USFDA approval for Alzheimer’s treatment trials
By 황유미Published : Oct. 24, 2016 - 16:12
[THE INVESTOR] Nature Cell announced on Oct. 24 that it has filed for approval of the US Food and Drug Administration to initiate the first and second phases of clinical trials for AstroStem, a stem cell therapy for Alzheimer’s disease, in the US.
Since 2008, Nature Cell has been seeking to develop a novel medicine for the still-incurable brain disease. Its CEO Ra Jeong-chan and a team from Seoul National University jointly had confirmed the possibility of a therapy using autologous adipose tissue on animals suffering from the degenerative disease, a first in the world.
The company has resumed research and development of the drug since December 2014 and when it receives approval from South Korean Ministry of Food and Drug Safety, it will recruit patients both here and in the US, aiming to complete the trials, simultaneously on the safety and efficacy, by the first half of 2017.
By Hwang You-mee (glamazon@heraldcorp.com)
Since 2008, Nature Cell has been seeking to develop a novel medicine for the still-incurable brain disease. Its CEO Ra Jeong-chan and a team from Seoul National University jointly had confirmed the possibility of a therapy using autologous adipose tissue on animals suffering from the degenerative disease, a first in the world.
The company has resumed research and development of the drug since December 2014 and when it receives approval from South Korean Ministry of Food and Drug Safety, it will recruit patients both here and in the US, aiming to complete the trials, simultaneously on the safety and efficacy, by the first half of 2017.
By Hwang You-mee (glamazon@heraldcorp.com)
![[Today’s K-pop] BTS pop-up event to come to Seoul](http://res.heraldm.com/phpwas/restmb_idxmake.php?idx=642&simg=/content/image/2024/04/17/20240417050734_0.jpg&u=)